Tags

Type your tag names separated by a space and hit enter

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.
Ann Oncol. 2013 Mar; 24(3):661-8.AO

Abstract

BACKGROUND

The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis.

PATIENTS AND METHODS

We explored patterns of recurrence in 4837 women with breast cancer defined as Luminal B (ER-positive and/or PgR-positive, HER2 positive and/or Ki-67≥14%) by IHC classification. We evaluated four subgroups within the Luminal B subtype according to HER2 expression and PgR status.

RESULTS

Patients within the ER+/PgR+/HER2- subgroup presented a 5-year breast cancer-related survival (BCS) of 97% (95% confidence interval (CI), 96-97) and overall survival (OS) of 95% [95% CI, 95-96], the best survivals of the Luminal B subgroups. In the multivariate analysis, the ER+/PgR-/HER2- subgroup was associated with a reduced BCS (HR 1.71; 95%CI, 1.25-2.35) and OS (HR 1.47; 95%CI, 1.10-1.96) when compared with the ER+/PgR+/HER2- subgroup. Also patients within the ER+/PgR-/HER2+ subgroup had a reduced BCS (HR 1.93; 95%CI, 1.32-2.83) and OS (HR 1.62; 95%CI, 1.14-2.30) when compared with ER+/PgR+/HER2- subgroup. On the other hand, no statistically significant differences were found with regard to BCS and OS among patients with ER+/PgR+/HER2+ and patients with ER+/PgR+/HER2- disease.

CONCLUSIONS

PgR loss identifies Luminal B breast cancer subgroups at higher risk of relapse and death, both with HER-2-positive and HER-2-negative disease.

Authors+Show Affiliations

Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan 20141, Italy. giuseppe.cancello@ieo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23022996

Citation

Cancello, G, et al. "Progesterone Receptor Loss Identifies Luminal B Breast Cancer Subgroups at Higher Risk of Relapse." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 24, no. 3, 2013, pp. 661-8.
Cancello G, Maisonneuve P, Rotmensz N, et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol. 2013;24(3):661-8.
Cancello, G., Maisonneuve, P., Rotmensz, N., Viale, G., Mastropasqua, M. G., Pruneri, G., Montagna, E., Iorfida, M., Mazza, M., Balduzzi, A., Veronesi, P., Luini, A., Intra, M., Goldhirsch, A., & Colleoni, M. (2013). Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 24(3), 661-8. https://doi.org/10.1093/annonc/mds430
Cancello G, et al. Progesterone Receptor Loss Identifies Luminal B Breast Cancer Subgroups at Higher Risk of Relapse. Ann Oncol. 2013;24(3):661-8. PubMed PMID: 23022996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. AU - Cancello,G, AU - Maisonneuve,P, AU - Rotmensz,N, AU - Viale,G, AU - Mastropasqua,M G, AU - Pruneri,G, AU - Montagna,E, AU - Iorfida,M, AU - Mazza,M, AU - Balduzzi,A, AU - Veronesi,P, AU - Luini,A, AU - Intra,M, AU - Goldhirsch,A, AU - Colleoni,M, Y1 - 2012/09/28/ PY - 2012/10/2/entrez PY - 2012/10/2/pubmed PY - 2013/7/31/medline SP - 661 EP - 8 JF - Annals of oncology : official journal of the European Society for Medical Oncology JO - Ann Oncol VL - 24 IS - 3 N2 - BACKGROUND: The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis. PATIENTS AND METHODS: We explored patterns of recurrence in 4837 women with breast cancer defined as Luminal B (ER-positive and/or PgR-positive, HER2 positive and/or Ki-67≥14%) by IHC classification. We evaluated four subgroups within the Luminal B subtype according to HER2 expression and PgR status. RESULTS: Patients within the ER+/PgR+/HER2- subgroup presented a 5-year breast cancer-related survival (BCS) of 97% (95% confidence interval (CI), 96-97) and overall survival (OS) of 95% [95% CI, 95-96], the best survivals of the Luminal B subgroups. In the multivariate analysis, the ER+/PgR-/HER2- subgroup was associated with a reduced BCS (HR 1.71; 95%CI, 1.25-2.35) and OS (HR 1.47; 95%CI, 1.10-1.96) when compared with the ER+/PgR+/HER2- subgroup. Also patients within the ER+/PgR-/HER2+ subgroup had a reduced BCS (HR 1.93; 95%CI, 1.32-2.83) and OS (HR 1.62; 95%CI, 1.14-2.30) when compared with ER+/PgR+/HER2- subgroup. On the other hand, no statistically significant differences were found with regard to BCS and OS among patients with ER+/PgR+/HER2+ and patients with ER+/PgR+/HER2- disease. CONCLUSIONS: PgR loss identifies Luminal B breast cancer subgroups at higher risk of relapse and death, both with HER-2-positive and HER-2-negative disease. SN - 1569-8041 UR - https://www.unboundmedicine.com/medline/citation/23022996/Progesterone_receptor_loss_identifies_Luminal_B_breast_cancer_subgroups_at_higher_risk_of_relapse_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0923-7534(19)37122-4 DB - PRIME DP - Unbound Medicine ER -